Patent · US Active

Identification and engineering of antibodies with variant Fc regions and methods of using same

US8003774B2 · kind B2 · utility

67Cited by
56References
52Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 30, 2008
Grant dateAug 23, 2011
Priority date
Expiry dateMar 6, 2029

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/70535
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.